Literature DB >> 17076335

Retrospective study of five-year clinical performance of direct composite restorations using a self-etching primer adhesive system.

Toru Nikaido1, Tsunehiko Takada, Yuichi Kitasako, Miwako Ogata, Yasushi Shimada, Takako Yoshikawa, Masatoshi Nakajima, Masayuki Otsuki, Junji Tagami, Michael F Burrow.   

Abstract

This study was conducted to assess the five-year clinical performance of composite restorations using a self-etching primer adhesive system, Clearfil Liner Bond II. Restorations were rated using the following scale: A--Good; B--Clinically acceptable; C--Clinically unacceptable; or D--Already replaced. The ratings were analyzed using Freedman's test (p=0.01) and Steel-Dwass test (p=0.05). A total of 83 restorations from 36 patients were identified from treatment records. Twenty-six restorations (31.3%) presented A rating and 36 restorations (43.4%) were clinically acceptable (B rating), while five (6.0%) received C rating and 16 (19.3%) had already been replaced (D rating). The mean survival rate of serviceable restorations (i.e., combined A and B ratings) after five years was 74.7%. It was found that cavity form, including cavity size, and occlusal contact seemed to influence longevity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17076335     DOI: 10.4012/dmj.25.611

Source DB:  PubMed          Journal:  Dent Mater J        ISSN: 0287-4547            Impact factor:   2.102


  2 in total

1.  A 24-month evaluation of amalgam and resin-based composite restorations: Findings from The National Dental Practice-Based Research Network.

Authors:  Michael S McCracken; Valeria V Gordan; Mark S Litaker; Ellen Funkhouser; Jeffrey L Fellows; Douglass G Shamp; Vibeke Qvist; Jeffrey S Meral; Gregg H Gilbert
Journal:  J Am Dent Assoc       Date:  2013-06       Impact factor: 3.634

2.  Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.

Authors:  Marica Peron; Paolo Bonvini; Angelo Rosolen
Journal:  BMC Cancer       Date:  2012-06-12       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.